[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 17, 1996

Clozapine for Treatment of Schizophrenia

Author Affiliations

Loma Linda University Medical Center Loma Linda, Calif

JAMA. 1996;275(3):186-187. doi:10.1001/jama.1996.03530270026023
Abstract

To the Editor.  —In an article in the series Grand Rounds at the Clinical Center of the National Institutes of Health, Drs Pickar and Hsiao1 reported a selected patient who participated in a double-blind clinical trial showing that clozapine is effective in the treatment of refractory schizophrenia. The research protocol used placebos. While some authors attempt to justify the use of placebo controls in clinical trials for schizophrenia,2 others condemn placebo usage when effective treatment is known.3Although their case report is not intended to be a report of the research, their allusion to the study without citation raises some important questions. The authors report, "Placebo substitution was followed by rapid increases in symptoms of schizophrenia." Was this psychotic patient able to give valid consent? Did she clearly understand that she would be on no treatment for some period of time? How long was this patient's condition

×